'Conditional Survival' Relevant for Metastatic RCC Prognosis

Share this content:
ChemotherapyAdvisor – Assessing patients using “conditional survival” adjusts the prognosis of patients with metastatic renal cell carcinoma (RCC) based on survival since time since treatment initiation with first-line VEGF-targeted therapy and “might be especially relevant” for poor-risk patients, investigators reported in The Lancet Oncology Online First August 7.

With the advent of targeted therapy, median survival for patients with metastatic RCC has been extended over the past 7 years, necessitating more accurate prognostic measures. The investigators analyzed data on 1,673 patients with metastatic RCC treated with a first-line VEGF-targeted therapy between April 7, 2003, and October 12, 2010, from the International mRCC Database Consortium comprising institutions in Canada, the United States, Singapore, Denmark, and South Korea.

Primary outcome was 2-year conditional survival, “defined as the probability of surviving an additional 2 years from a given timepoint since the start of targeted therapy. Secondary analyses included 1-year and 3-year conditional survival, along with stratification of patients by Heng prognostic risk criteria and Karnofsky performance score, and conditional survival based on length of time on therapy,” they wrote.

For living patients, median follow-up was 20.1 months. The 2-year conditional survival probability increased from 44% (95% CI 41%—47%) at 0 months to 51% (46%—55%) at 18 months since beginning targeted therapy.

“When stratified by the Heng prognostic risk criteria defined at therapy initiation, 2-year conditional survival changed little in the favorable and intermediate groups, but in the poor-risk group, 2-year conditional survival improved from 11% (8%—15%) at 0 months to 33% (18%—48%) after 18 months,” they noted.

“When conditioned on time on targeted therapy from 0 months to 18 months, 2-year conditional survival improved from 44% (41%—47%) to 68% (60%—75%) in the overall population and from 74% (68%—79%) to 90% (77%—96%) in the favorable group, 49% (45%—53%) to 57% (45%—67%) in the intermediate group, and 11% (8%—15%) to 73% (43%—89%) in the poor-risk group,” they concluded.

Abstract

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs